Affordable production of pathogen inactivated platelet concentrates

Karolinska University Hospital in Stockholm, Sweden, produces about 9,000 units of buffy coat derived platelets (BCPs) per year for patient use. Until 2014, BCPs were produced using the OrbiSac System together with the enhanced Bacterial Detection System (eBDS™) as a blood safety measure. To further improve blood safety, pathogen inactivation (PI) was considered. However, the challenge was to implement PI without increasing the costs. A feasible solution was a combination of the INTERCEPT™ Blood System and manual production of double dose buffy coat derived platelets (DD-BCPs).
Use of INTERCEPT plasma or platelets is contraindicated in patients with a history of allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings and precautions.